Advances in treatment of primary biliary cirrhosis

QIN Hua; BAI Shishan
September 2013
Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;sep2013, Vol. 29 Issue 9, following p719
Academic Journal
Primary biliary cirrhosis (PBC) is a chronic progressive intrahepatic cholestatic disease of unknown cause, and its incidence is increasing year by year. The main therapies for PBC include ursodeoxycholic acid for cholestasis, glucocorticoid or immunosuppressant for abnormal immune response, and symptomatic treatment for complications; liver transplantation is suitable for end - stage cases. With continuous development and clinical application of new drugs, this paper reviews the latest global advances in the treatment of PBC over the last 5 years. However, further study is needed to identify the radical treatment with fewest adverse effects.


Related Articles

  • Clinical features and management of primary biliary cirrhosis. Crosignani, Andrea; Battezzati, Pier Maria; Invernizzi, Pietro; Selmi, Carlo; Prina, Carlo; Podda, Mauro // World Journal of Gastroenterology;6/7/2008, Vol. 14 Issue 21, p3313 

    Primary biliary cirrhosis (PBC), which is characterised by progressive destruction of intrahepatic bile ducts, is not a rare disease since both prevalence and incidence are increasing during the last years mainly due to the improvement of case finding strategies. The prognosis of the disease has...

  • Ursodeoxycholic acid in obstetric cholestasis.  // Africa Health;Jan2020, Vol. 42 Issue 1, p36 

    No abstract available.

  • Ursodeoxycholic acid.  // Reactions Weekly;Sep2014, Vol. 1520 Issue 1, p212 

    The article presents a case study of a 59-year old male patient who developed a fixed drug eruption during treatment of ursodeoxycholic acid for cholestasis.

  • Ursodeoxycholic Acid and Long-Term Survival in Primary Biliary Cirrhosis. Levy, Cynthia // American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p269 

    Comments on issues about the potential therapeutic value of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). Use of orthotopic liver transplantation (OLT) to cure PBC; Investigation on the extent of benefit of UDCA therapy with or without OLT; Significance of the study on the...

  • Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. Kuiper, Edith M. M.; Hansen, Bettina E.; Metselaar, Herold J.; de Man, Robert A.; Haagsma, Els B.; van Hoek, Bart; van Buuren, Henk R. // BMC Gastroenterology;2010, Vol. 10, p144 

    Background: A decrease in the need for liver transplantations (LTX) in Primary Biliary Cirrhosis (PBC), possibly related to treatment with ursodeoxycholic acid (UDCA), has been reported in the USA and UK. The aim of this study was to assess LTX requirements in PBC over the past 20 years in the...

  • Effect of Ursodeoxycholic Acid Administration after Liver Transplantation on Serum Liver Tests and Biliary Complications: A Randomized Clinical Trial. Wang, Shu-Yun; Tang, Hua-Mei; Chen, Guo-Qing; Xu, Jun-Ming; Zhong, Lin; Wang, Zhao-Wen; Deng, Gui-Long; Xing, Tong-Hai; Lu, Lun-Gen; Peng, Zhi-Hai // Digestion;2012, Vol. 86 Issue 3, p208 

    Background/Aims: Endogenous hydrophobic bile acids are suspected to be one of the pathogenetic factors of biliary complications after orthotopic liver transplantation (OLT). This study was designed to investigate the effects of hydrophilic ursodeoxycholic acid (UDCA) administration early after...

  • Immunosuppressive Agents for the Treatment of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis. Peng, Xia; Luo, Xin; Hou, Jing-Ying; Wu, Shu-Yun; Li, Liang-Zong; Zheng, Ming-Hua; Wang, Ling-Yun // Digestive Diseases;Aug2017, Vol. 35 Issue 5, p478 

    Objectives: Currently, there are no effective therapeutic agents for patients with primary sclerosing cholangitis (PSC). This study aimed to evaluate the safety and efficiency of immunosuppressive agents (IAs) for the treatment of PSC. Methods: The literatures were searched using the following...

  • Mesenchymal Stem Cells with Enhanced Bcl-2 Expression Promote Liver Recovery in a Rat Model of Hepatic Cirrhosis. Shizhu Jin; Hulun Li; Mingzi Han; Mengting Ruan; Zishuai Liu; Feifei Zhang; Chunwei Zhang; Yongsub Choi; Bingrong Liu // Cellular Physiology & Biochemistry (Karger AG);Dec2016, Vol. 40 Issue 5, p1117 

    Background/Aims: Mesenchymal stem cell (MSC) transplantation has emerged as an option for the treatment of chronic hepatic cirrhosis, while its therapeutic efficacy could be improved. The bcl-2 gene is anti-apoptotic and can help cell survival and proliferation. Therefore, we explored whether...

  • Triple antiviral therapy with telaprevir after liver transplantation: a case series. Knapstein, Johanna; Grimm, Daniel; W├Ârns, Marcus A; Galle, Peter R.; Lang, Hauke; Zimmermann, Tim // Transplant Research & Risk Management;2014, Vol. 6, p73 

    Introduction: Hepatitis C virus (HCV) reinfection occurs universally after liver transplantation, with accelerated cirrhosis rates of up to 30% within 5 years after liver transplantation. Dual antiviral therapy with pegylated interferon-2a (peg-IFN) and ribavirin (RBV) only reaches sustained...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics